Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.66 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.66 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.66 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.56 |
| ▸ | IKBKB | O14920 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27768646 | 0.85 | ALDH1A1 (0.74) | ALDH1A1HDAC1HDAC8HDAC6PDE4B | |
| SCHEMBL287420 | 0.85 | ALDH1A1 (0.74) | ALDH1A1HDAC1HDAC8HDAC6PDE4B | |
| SCHEMBL21689255 | 0.84 | ALDH1A1 (0.73) | ALDH1A1HDAC1HDAC8HDAC6PDE4B | |
| SCHEMBL27808017 | 0.84 | ALDH1A1 (0.73) | ALDH1A1HDAC1HDAC8HDAC6PDE4B | |
| SCHEMBL27721487 | 0.84 | ALDH1A1 (0.73) | ALDH1A1HDAC1HDAC8HDAC6PDE4B | |
| SCHEMBL168220 | 0.83 | ALDH1A1 (0.71) | ALDH1A1HDAC1HDAC8HDAC6PDE4B | |
| SCHEMBL28033118 | 0.83 | ALDH1A1 (0.71) | ALDH1A1HDAC1HDAC8HDAC6PDE4B | |
| SCHEMBL30090095 | 0.82 | ALDH1A1 (0.69) | ALDH1A1HDAC1HDAC8HDAC6PDE4B | |
| SCHEMBL31661941 | 0.82 | ALDH1A1 (0.69) | ALDH1A1HDAC1HDAC8HDAC6PDE4B | |
| SCHEMBL6706804 | 0.82 | ALDH1A1 (0.70) | ALDH1A1HDAC1HDAC8HDAC6PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119768164-A | Pharmaceutical compounds for treating complement-mediated disorders | 阿雷克森制药公司 | 2025-04-04 | — | — | CN | disclosed |
| EP-4200284-A1 | LMO2 PROTEIN INHIBITORS | University of Oxford (GB) | 2023-06-28 | — | — | EP | disclosed |
| US-20220133740-A1 | VALPROIC ACID COMPOUNDS AND WNT AGONISTS FOR TREATING EAR DISORDERS | Frequency Therapeutics, Inc. (US) | 2022-05-05 | — | — | US | disclosed |
| US-11319347-B2 | Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound | FUJIFILM CORPORATION (JP) | 2022-05-03 | — | — | US | disclosed |
| WO-2022038356-A1 | LMO2 PROTEIN INHIBITORS | UNIVERSITY OF OXFORD (GB) | 2022-02-24 | — | — | WO | disclosed |
| US-20200040039-A1 | PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME, COMPOSITION FOR SCREENING USE, AND METHOD FOR SELECTING PEPTIDE COMPOUND | FUJIFILM CORPORATION (JP) | 2020-02-06 | — | — | US | disclosed |
| US-20190054068-A1 | Indole Amide Derivatives and Related Compounds for Use in the Treatment of Neurodegenerative Diseases | REMYND (BE) | 2019-02-21 | — | — | US | disclosed |
| EP-2822944-A1 | OXAZOLIDINONE COMPOUNDS AND DERIVATIVES THEREOF | AMGEN, INC. (US) | 2015-01-14 | — | — | EP | disclosed |
| US-8729270-B2 | Anti-cancer compounds, synthesis thereof, and methods of using same | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729270-B2 | Anti-cancer compounds, synthesis thereof, and methods of using same | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2014-05-20 | — | — | US | disclosed |
| EP-2649068-A1 | OXAZOLYL-METHYLETHER DERIVATIVES AS ALX RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2013-10-16 | — | — | EP | disclosed |
| WO-2013134079-A1 | OXAZOLIDINONE COMPOUNDS AND DERIVATIVES THEREOF | AMGEN INC. (US) | 2013-09-12 | — | — | WO | disclosed |
| US-20120289704-A1 | ANTI-CANCER COMPOUNDS, SYNTHESIS THEREOF, AND METHODS OF USING SAME | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120289704-A1 | ANTI-CANCER COMPOUNDS, SYNTHESIS THEREOF, AND METHODS OF USING SAME | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120289704-A1 | ANTI-CANCER COMPOUNDS, SYNTHESIS THEREOF, AND METHODS OF USING SAME | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2012-11-15 | — | — | US | disclosed |
| US-8268874-B2 | Anti-cancer compounds, synthesis thereof, and methods of using same | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2012-09-18 | — | — | US | disclosed |
| WO-2012077049-A1 | OXAZOLYL-METHYLETHER DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-06-14 | — | — | WO | disclosed |
| US-20120083475-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2012-04-05 | — | — | US | disclosed |
| US-20110021574-A1 | ANTI-CANCER COMPOUNDS, SYNTHESIS THEREOF, AND METHODS OF USING SAME | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2011-01-27 | — | — | US | disclosed |
| WO-2009111502-A2 | ANTI-CANCER COMPOUNDS, SYNTHESIS THEREOF, AND METHODS OF USING SAME | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083475-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, MAPT, NLN | ALDH1A1 2395/4885HDAC1 2284/4885HDAC8 1575/4885 |
| US-20200040039-A1 | PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME, COMPOSITION FOR SCREENING USE, AND METHOD FOR SELECTING PEPTIDE COMPOUND | VIP, NPPA, NGLY1 | ALDH1A1 4809/4885HDAC1 4286/4885HDAC8 4140/4885 |
| US-20110021574-A1 | ANTI-CANCER COMPOUNDS, SYNTHESIS THEREOF, AND METHODS OF USING SAME | MCL1, BRDT, GLS | ALDH1A1 569/4885HDAC1 1633/4885HDAC8 691/4885 |
| US-20190054068-A1 | Indole Amide Derivatives and Related Compounds for Use in the Treatment of Neurodegenerative Diseases | SNCA, MAPT, NLN | ALDH1A1 2395/4885HDAC1 2284/4885HDAC8 1575/4885 |
| US-20120289704-A1 | ANTI-CANCER COMPOUNDS, SYNTHESIS THEREOF, AND METHODS OF USING SAME | MCL1, BRDT, GLS | ALDH1A1 569/4885HDAC1 1633/4885HDAC8 691/4885 |
| US-11319347-B2 | Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound | VIP, NPPA, NGLY1 | ALDH1A1 4809/4885HDAC1 4286/4885HDAC8 4140/4885 |
| US-20220133740-A1 | VALPROIC ACID COMPOUNDS AND WNT AGONISTS FOR TREATING EAR DISORDERS | WNT3A, WNT1, WNT3 | ALDH1A1 455/4885HDAC1 226/4885HDAC8 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.